Innoviva (INVA) Amortization of Deferred Charges (2013 - 2026)

Innoviva (INVA) posted Amortization of Deferred Charges of $364000.0 for Q1 2026, down 76.26% on a QoQ basis from $1.5 million in Q3 2025, and down 32.72% year-over-year from $541000.0 in Q1 2025.

Innoviva (INVA) Amortization of Deferred Charges (2013 - 2026) Analysis & Trends

Innoviva's Amortization of Deferred Charges history runs 14 years deep, the most recent figure standing at $364000.0 for Q1 2026.

  • Quarterly Amortization of Deferred Charges fell 32.72% year-over-year to $364000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $3.0 million (down 6.15% YoY) and the FY2025 annual result came in at $1.9 million, down 10.57% from the prior year.
  • Amortization of Deferred Charges was $364000.0 for Q1 2026 at Innoviva, down from $1.5 million in the prior quarter.
  • Across five years, Amortization of Deferred Charges topped out at $1.6 million in Q3 2024 and bottomed at $364000.0 in Q1 2026.
  • A 5-year average of $815923.1 and a median of $537000.0 in 2025 frame the typical range for Amortization of Deferred Charges.
  • Annual changes were most pronounced in 2022 — Amortization of Deferred Charges sank 82.95% — and 2023, when it surged 38.73%.
  • Innoviva's Amortization of Deferred Charges stood at $1.5 million in 2022, then gained by 3.89% to $1.5 million in 2023, then rose by 2.07% to $1.6 million in 2024, then slipped by 3.04% to $1.5 million in 2025, then sank by 76.26% to $364000.0 in 2026.
  • Business Quant data shows INVA's Amortization of Deferred Charges at $364000.0 in Q1 2026, $1.5 million in Q3 2025, and $537000.0 in Q2 2025.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Oculis Holding AG 67,072.09 Bn 67,071.81 Bn -
2 Nanobiotix 1,925.70 Bn 1,925.64 Bn -
3 Akari Therapeutics 1,062.88 Bn 1,062.88 Bn -
4 BeOne Medicines 469.09 Bn 464.29 Bn 1.35 Bn
5 Vertex Pharmaceuticals 123.09 Bn 115.84 Bn 2.59 Bn
6 Regeneron Pharmaceuticals 70.32 Bn 61.57 Bn 3.31 Bn
7 Belite Bio 63.36 Bn 63.36 Bn -
8 Argenx Se 55.90 Bn 50.71 Bn 1.41 Bn
9 Alnylam Pharmaceuticals 37.69 Bn 34.68 Bn 959.66 Mn
10 Innoviva 1.61 Bn 1.01 Bn 75.83 Mn

Historic Data

Download Data
DateValue
Mar 31, 2026 364,000.00
Mar 31, 2026 364,000.00
Sep 30, 2025 1.53 Mn
Sep 30, 2025 1.53 Mn
Jun 30, 2025 537,000.00
Jun 30, 2025 537,000.00
Mar 31, 2025 541,000.00
Mar 31, 2025 541,000.00
Sep 30, 2024 1.58 Mn
Sep 30, 2024 1.58 Mn
Jun 30, 2024 523,000.00
Jun 30, 2024 523,000.00
Mar 31, 2024 525,000.00
Mar 31, 2024 525,000.00
Sep 30, 2023 1.55 Mn
Sep 30, 2023 1.55 Mn
Jun 30, 2023 509,000.00
Jun 30, 2023 509,000.00
Mar 31, 2023 523,000.00
Mar 31, 2023 523,000.00